MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Spanning nine influenza seasons, these studies enrolled 1862 patients, of whom 954 received the high-dose vaccine and 908 the standard-dose vaccine. Primary outcomes were immunogenicity (measured ...

The Subject Expert Committee (SEC) under the COVID-19 division of the Central Drugs Standard Control Organization (CDSCO) has ...

"An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic ... pivotal efficacy, immunogenicity and ...

Immunogenicity of Trivalent Influenza Vaccine in Extremely Low-birth-weight, Premature versus Term Infants. ... (HA) units in 0.025 mL of the virus suspension. H1, H3, B/Victoria, ...

In opening Wednesday’s meeting, newly appointed ACIP chair Martin Kulldorff, Ph.D., leaned into the controversy surrounding U ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Apr. 23, 2025 — A vaccine under development has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work focuses on the H5N1 variant known as ...

Apr. 22, 2025 — A multi-state study reveals that many high-risk adults diagnosed with influenza (flu) in emergency departments and urgent care centers are not receiving timely antiviral treatment.

Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu ...